stockrowRoivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) Net income
Roivant Sciences Ltd.'s net income for fiscal 2026 was −$397.9M, compared with −$356.7M in fiscal 2025. Over the twelve months to 30 June 2026 it was −$414.6M. Over the past ten years it has ranged from −$1.1B (fiscal 2023) to $4.2B (fiscal 2024); the current reading is higher than 50% of that period. Roivant Sciences Ltd. ranks 577th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2026 | −$397.9M | — |
| FY2025 | −$356.7M | — |
| FY2024 | $4.2B | — |
| FY2023 | −$1.1B | — |
| FY2022 | −$924.1M | — |
| FY2021 | −$900.2M | — |
| FY2020 | −$386.4K | — |
| FY2018 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$290.6M | — |
| Mar 2026 | $355.7M | — |
| Dec 2025 | −$313.7M | — |
| Sep 2025 | −$166.0M | — |
| 21 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | $2.6B |
| RPRX Royalty Pharma PLC compare | $1.3B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $915.6M |
| GMAB Genmab A/S Sponsored ADR compare | $906.0M |
| INCY Incyte Corporation compare | $403.4M |
| ROIV Roivant Sciences Ltd. | −$414.6M |
| INSM Insmed, Inc. compare | −$605.6M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.6B |
| RVMD Revolution Medicines, Inc. compare | −$1.9B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ROIV
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement